Common variable immunodeficiency: etiological and treatment issues.
One of the great advances in clinical medicine was the recognition of the pleomorphism of the immune response and the multiple afferent and efferent limbs of antigen processing and responsiveness. A significant contribution to this understanding was derived from studies of human immunodeficiency states, including both inherited and acquired syndromes. Amongst these syndromes, one of the most common, and least understood, is common variable immune deficiency (CVID). CVID is a syndrome that leads to a reduction in serum immunoglobulins and complications including recurrent infections. Management includes immunoglobulin replacement therapy; however, patients with CVID are at risk for complications of exogenous immunoglobulin administration as well as CVID-associated diseases such as autoimmune processes and malignancies. To assess the current state of knowledge in the field, we performed a literature review of a total of 753 publications covering the period of 1968 until 2008. From this list, 189 publications were selected for discussion. In this review, we demonstrate that while the molecular basis of CVID in many cases remains incompletely understood, significant strides have been made and it is now clear that there is involvement of several pathways of immune activation, with contributions from both T and B cells. Furthermore, despite the current gaps in our knowledge of the molecular pathogenesis of the syndrome, there have been dramatic advances in management that have led to improved survival and significantly reduced morbidity in affected patients.
Deane
Sean
S
Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Davis, California 95616, USA.
Selmi
Carlo
C
Naguwa
Stanley M
SM
Teuber
Suzanne S
SS
Gershwin
M Eric
ME
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000209:etiology / Q000517:prevention & control; D001402:B-Lymphocytes / Q000276:immunology*; D017074:Common Variable Immunodeficiency / Q000150:complications / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007239:Infections / Q000209:etiology / Q000628:therapy; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000209:etiology / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology
D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous